Buyer Beware of This $1 Million Gene Therapy for Aging
December 9, 2019
(MIT Technology Review) – While telomere-extending treatments in mice have yielded intriguing results, nobody has demonstrated that tweaking the molecular clocks has benefits for humans. That isn’t stopping one US startup from advertising a telomere-boosting genetic therapy—at a price. Libella Gene Therapeutics, based in Manhattan, Kansas, claims it is now offering a gene therapy to repair telomeres at a clinic in Colombia for $1 million a dose. The company announced on November 21 that it was recruiting patients into what it termed a “pay-to-play clinical trial.” Buyer beware, though: this “trial” is for an unproven, untested treatment that might even be harmful to your health.